These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8372729)

  • 1. Variability in response to D-penicillamine: pharmacokinetic insights.
    Joyce DA
    Agents Actions Suppl; 1993; 44():203-7. PubMed ID: 8372729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced intracellular delivery of the reactive oxygen species (ROS)-generating copper chelator D-penicillamine via a novel gelatin--D-penicillamine conjugate.
    Gupte A; Wadhwa S; Mumper RJ
    Bioconjug Chem; 2008 Jul; 19(7):1382-8. PubMed ID: 18570451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-penicillamine metabolism: the role of transformation in blood plasma.
    Joyce DA; Murphy BR
    Agents Actions; 1990 Nov; 31(3-4):353-7. PubMed ID: 2085148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of albumin conjugates of D-penicillamine in rats.
    Joyce DA; Wade DN; Swanson BR
    Drug Metab Dispos; 1989; 17(2):208-11. PubMed ID: 2565212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-penicillamine pharmacokinetics and action.
    Joyce DA
    Agents Actions Suppl; 1988; 24():197-206. PubMed ID: 3263758
    [No Abstract]   [Full Text] [Related]  

  • 6. Copper chelation by D-penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells.
    Gupte A; Mumper RJ
    Free Radic Biol Med; 2007 Nov; 43(9):1271-8. PubMed ID: 17893040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-penicillamine metabolism in an in-vivo model of inflamed synovium.
    Joyce DA; Forrest MJ; Brooks PM
    Agents Actions; 1988 Dec; 25(3-4):336-43. PubMed ID: 3218609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An outline of D-penicillamine metabolism.
    Perrett D
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):61-4. PubMed ID: 122676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficient sulphoxidation status and D-penicillamine toxicity.
    Panayi GS; Huston G; Shah RR; Mitchell SC; Idle JR; Smith RL; Waring RH
    Lancet; 1983 Feb; 1(8321):414. PubMed ID: 6130402
    [No Abstract]   [Full Text] [Related]  

  • 10. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo inhibition of activation induced T cell apoptosis by bucillamine.
    Okazaki H; Sato H; Kamimura T; Hirata D; Iwamoto M; Yoshio T; Mimori A; Masuyama JI; Kano S; Minota S
    J Rheumatol; 2000 Jun; 27(6):1358-64. PubMed ID: 10852254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation into copper catalyzed D-penicillamine oxidation and subsequent hydrogen peroxide generation.
    Gupte A; Mumper RJ
    J Inorg Biochem; 2007 Apr; 101(4):594-602. PubMed ID: 17275091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Free radicals and antioxidants: human physiology, pathology and therapeutic aspects].
    Sahnoun Z; Jamoussi K; Zeghal KM
    Therapie; 1997; 52(4):251-70. PubMed ID: 9437876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aging brain, metals and oxygen free radicals.
    Samson FE; Nelson SR
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):699-707. PubMed ID: 10875433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro mechanism of oxidation of D-penicillamine in plasma.
    Joyce DA
    J Pharm Sci; 1991 Mar; 80(3):289-92. PubMed ID: 2051347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma D-penicillamine redox state evaluation by capillary electrophoresis with laser-induced fluorescence.
    Zinellu A; Carru C; Sotgia S; Deiana L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(2):299-304. PubMed ID: 15063339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of methotrexate induced nodulosis with D-penicillamine.
    Dash S; Seibold JR; Tiku ML
    J Rheumatol; 1999 Jun; 26(6):1396-9. PubMed ID: 10381063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine.
    Katayama Y; Kohriyama K; Matsui T
    J Rheumatol; 1999 Nov; 26(11):2493-5. PubMed ID: 10555917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.